Divalproex Sodium Tablet, Film Coated, Extended Release
Product Images NDC 71335-2535

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 71335-2535). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image
Camberlogo (Camberlogo)
FDA Label Image

Figure-1 (Figure 1)

Figure-1 (Figure 1)
A line graph comparing the percentage reduction in CPS (complex partial seizures) rate between Divalproex Sodium Delayed-Release Tablets and placebo across a percentage of patients. The vertical axis represents the percent reduction in CPS rate ranging from -100% to 100%, with labels indicating improvement or worsening. The horizontal axis shows the percentage of patients from 0 to 100%. Two curves are shown: a solid line for Divalproex Sodium and a dashed line for placebo, illustrating greater improvement with Divalproex Sodium over placebo.*
FDA Label Image

Figure-2 (Figure 2)

Figure-2 (Figure 2)
A line graph depicting the percentage reduction in CPS rate versus the percentage of patients for High Dose and Low Dose Divalproex Sodium Delayed-Release Tablets. The vertical axis shows improvement and worsening, with a horizontal line indicating no change, while the horizontal axis represents the percentage of patients.*
FDA Label Image

Figure-3 (Figure 3)

Figure-3 (Figure 3)
A bar chart comparing placebo and Divalproex Sodium Extended-Release Tablets. The chart shows numerical values on the vertical axis, with placebo represented by an open bar and Divalproex Sodium by a filled bar. The Divalproex Sodium bar is higher, labeled 1.2, and the placebo bar is labeled 0.6, with a p-value of 0.006 indicated.*
FDA Label Image

Label (Lbl713352535)

Label (Lbl713352535)
Label for Divalproex Sodium Extended-Release Tablets USP, 500 mg, in a package of 60 tablets. The label features the NDC 71335-2535-1 and indicates the product is repackaged by Bryant Ranch Prepack, Inc., Burbank, CA, and manufactured by Annora Pharma Pvt. Ltd. Storage instructions and dispensing warnings are also visible.*
FDA Label Image

Structure (Structure)

Structure (Structure)
Chemical structure of divalproex sodium shown as a polymeric complex with repeating units. The diagram includes carboxylate groups coordinated with sodium ions and branched alkyl chains, representing the extended release salt form.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.